AARTIDRUGS vs KREBSBIO: Stock Comparison

AARTI DRUGS vs KREBS BIOCHEMICALS & INDUpdated 4 Sept 26, 4:08 PM ISTNSE & company filings

AARTI DRUGS is the larger company by market capitalisation. AARTI DRUGS shows a higher dividend yield, a higher ROCE and a higher net margin, while KREBS BIOCHEMICALS & IND shows a lower P/E and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

AARTIDRUGS leads 6; KREBSBIO leads 5 of 11

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

AARTIDRUGSKREBSBIO

Valuation lens

What price are you paying?

Market CapContext only
₹3,973 Cr
₹121 Cr
P/E RatioKREBSBIO has the lower reading
20x
0x
P/B RatioKREBSBIO has the lower reading
2.47x
0x
EPSAARTIDRUGS has the higher reading
₹5.57
₹-1.15
Book ValueContext only
₹169.74
Dividend YieldAARTIDRUGS has the higher reading
0.46%
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
AARTIDRUGS is the larger company
₹3,973 Cr vs ₹121 Cr
P/E Ratio
KREBSBIO has a lower P/E
0x vs 20x
P/B Ratio
KREBSBIO has a lower P/B
0x vs 2.47x
EPS
AARTIDRUGS has higher earnings per share
₹5.57 vs ₹-1.15
Dividend Yield
AARTIDRUGS has a higher dividend yield
0.46% vs 0%
Revenue Growth (TTM YoY)
KREBSBIO has faster revenue growth
11.6% vs 6.4%
EPS Growth (TTM YoY)
KREBSBIO has faster EPS growth
0% vs -12%
Qtr Sales Growth
AARTIDRUGS has stronger quarterly sales growth
-10.72% vs -70.57%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricAARTIDRUGSKREBSBIO
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricAARTIDRUGSKREBSBIO
Live Price₹431.65₹55.95
Day Change1.36%2.66%
Volume2.5 L5,830
52-Week High₹534.55₹82.49
52-Week Low₹318.95₹38.33
Distance from 52W High-19.25%-32.17%

Valuation

MetricAARTIDRUGSKREBSBIO
Market Cap₹3,973 Cr₹121 Cr
P/E Ratio20x0x
P/B Ratio2.47x0x
EPS₹5.57₹-1.15
Book Value₹169.74
Dividend Yield0.46%0%

Growth

MetricAARTIDRUGSKREBSBIO
Revenue Growth (TTM YoY)6.4%11.6%
EPS Growth (TTM YoY)-12%0%
Qtr Sales Growth-10.72%-70.57%
Qtr Profit Growth1.44%85.33%

Profitability & Leverage

MetricAARTIDRUGSKREBSBIO
ROE12.05%
ROCE10.64%-15.89%
Net Margin7.6%-71.35%
Operating Margin9.19%-41.49%
Debt to Equity0.3x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricAARTIDRUGSKREBSBIO
Promoter Holding54.43% 0.6 pp72.74%
FII Holding1.52% 0.06 pp0.5%
DII Holding10.29% 0.07 pp0%
Public Holding33.75% 0.57 pp26.76%

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: AARTI DRUGS and KREBS BIOCHEMICALS & IND.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.